



## Niger COVID-19 Emergency Response Project (P173846)

WESTERN AND CENTRAL AFRICA | Niger | Health, Nutrition & Population Global Practice |  
IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 5 | ARCHIVED on 29-Jul-2022 | ISR52434 |

Implementing Agencies: Ministry of Planning, Ministry of Public Health, Population and Social Affairs, Republic of Niger

### Key Dates

#### Key Project Dates

Bank Approval Date: 13-Apr-2020

Effectiveness Date: 08-Jul-2020

Planned Mid Term Review Date: 17-Oct-2022

Actual Mid-Term Review Date: 01-Jul-2022

Original Closing Date: 30-Apr-2022

Revised Closing Date: 31-Dec-2024

### Project Development Objectives

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness in Niger

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

### Components Table

Name

Component 1: Emergency COVID-19 Response:(Cost \$61.35 M)

Component 2: Communication campaign, community engagement and Behavior change:(Cost \$4.00 M)

Component 3: Implementation Management and Monitoring and Evaluation:(Cost \$4.50 M)

### Overall Ratings

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Moderately Satisfactory	<input type="checkbox"/> Moderately Satisfactory
Overall Risk Rating	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

### Implementation Status and Key Decisions

At mid-term review stage and based on the recorded implementation progress and the likelihood of achieving the project outcomes, both the implementation Progress (IP) and the Development Objectives (DO) are rated satisfactory. The second additional financing in the amount of US\$26.7 million was approved on June 20, 2022, bringing the total project financing to US\$69.85 million. All parent project financing has been disbursed or committed.

**COVID-19 vaccination status:** The response measures must be reinforced as the rate of vaccination is still low; the last vaccination campaign (sixth campaign) was just completed. Furthermore, the strategies of vacci-drones and mobile sites have shown promising results and have facilitated the country to double its vaccination coverage. As of July 17, Niger has recorded 12 percent of the total population to be fully vaccinated (i.e. 2,860,989 people) against the national target to cover 14,833,403 people (i.e. 58.41 percent of the total population).



## MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

## Multiphase Programmatic Approach (MPA) Status

The Additional Financing (MPA AF-V) to the COVID-19 Strategic Preparedness and Response Program utilizing the Multiphase Programmatic Approach (“Global COVID-19 MPA”) was approved by the Board on October 13, 2021. The AF-V was approved with an envelope of US\$12 billion (\$6 billion from IDA and \$6 billion from IBRD) in financing. **On June 30, 2021, President Malpass announced the expansion of financing available for COVID-19 vaccine financing to \$20 billion over the next 18 months, adding \$8 billion to the previously announced \$12 billion.** This financing is critical to expand affordable and equitable financing for vaccine purchase and deployment. The AF-V is expected to enable vaccination for up to 750 million people, with potential surge capacity for an additional 250 million people in the poorest countries (depending on the delivered price of approved vaccines) while scaling support to strengthen immunization delivery, with design flexibility at the country level. The AF-V is a scale-up of planned vaccination activities anticipated and supported under the Global COVID-19 MPA and a key contribution to the WBG’s overall COVID-19 response.

**As of July 15, 2022, the Bank has approved 115 operations (including MPA-V operations) to support vaccine procurement and rollout in 78 countries amounting to \$10.1 billion.** The 115 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project. Of the 115 approved operations: (i) 64 are in Africa – 29 in AFE and 35 in AFW; (ii) 9 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 13 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. Thirty-four (34) operations have been approved so far this Calendar Year. Fifty-nine (59) projects are disbursing. **Total disbursements as of July 15, 2022, under these projects amount to US\$3.98 billion or 40% of overall commitments.** Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. **Twenty-one (21) operations have disbursed over 70% of their commitments. Out of the 21, nine have disbursed 90%. Retroactive Financing (RF) represents 39% of overall commitments.** High RF has been authorized under different operations Indonesia and Ukraine (100%), Panama and Turkey (90%), Argentina and Guyana (80%), and Belize, Iraq and Sri Lanka (70%). Three (3) new operations are under various stages of processing. As with the MPA operations, streamlined procedures, delegated approval, coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design and processing of the operations. Ninety-seven (97) loan/financing agreements have been signed. Also, eighty-seven (87) loan/financing agreements have become effective; several others are expected to become effective in the coming weeks. Implementation of the AF-V operations, as with MPA operations is facing challenges as several countries are still under different levels of mobility restrictions and counterparts and Bank teams are operating in a hybrid environment with some days at the office and some at home. Virtual missions have continued to be the norm in some countries. Countries are continuing to deal with sharp increases of infections, as the Omicron variant continues to spread rapidly among populations. The omicron variant spread rapidly across the world, out-competing former variants soon after it was first detected in November, 2021.

## Risks

### Systematic Operations Risk-rating Tool

Risk Category	Rating at Approval	Previous Rating	Current Rating
---------------	--------------------	-----------------	----------------



Political and Governance	High	Substantial	Substantial
Macroeconomic	High	Substantial	Substantial
Sector Strategies and Policies	Moderate	Moderate	Moderate
Technical Design of Project or Program	Substantial	Moderate	Moderate
Institutional Capacity for Implementation and Sustainability	Moderate	Substantial	Substantial
Fiduciary	High	Substantial	Substantial
Environment and Social	Substantial	Substantial	Substantial
Stakeholders	Moderate	Substantial	Substantial
Other	--	Substantial	Substantial
Overall	Substantial	Substantial	Substantial

## Results

### PDO Indicators by Objectives / Outcomes

To prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for p				
► Efficiency of a public health coordination mechanism for COVID-19 (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Country has established its coordination mechanism for COVID-19 with daily reporting of different commissions			
► Suspected cases of COVID-19 cases reported and investigated based on national guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	99.81	99.81	100.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	30-Apr-2022
Comments:	Numerator: Number of suspected cases of COVID-19 cases reported and investigated based on national guidelines Denominator: Number of of suspected cases of COVID-19 cases reported and investigated			
► Laboratories with trained staff and consumables for collecting COVID-19 samples and transporting to the National Public Health Laboratory (Centre de Recherche Médicale et Sanitaire, CERMES) (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	17.00	17.00	20.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024



Comments:	Cumulative targeted laboratories equipped with COVID-19 diagnostic equipment			
▶ Targeted regions with pandemic preparedness and response plans per Ministry of Public Health Guidelines (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	100.00	100.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Numerator: number of targeted regions with pandemic level response plan according to Ministry of Public Health guidelines. Denominator: number of targeted regions			
▶ Population vaccinated, which is included in the priority population targets defined in national plan (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	4.20	4.20	15.00
Date	12-Mar-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
□ Population vaccinated, which is included in the priority population targets defined in national plan - Female (Percentage, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	1.50	1.50	6.00
Date	11-Jun-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024

### Intermediate Results Indicators by Components

Component 1: Emergency COVID-19 Response				
▶ Personal protective equipment (PPE) kits delivered to health facilities (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	500,000.00	500,000.00	12,000.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Cumulative number of PPE kits distributed to health facilities			
▶ Health staff trained in infection prevention per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	300.00	300.00	600.00



Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Cumulative number of staff receiving infection prevention control (IPC) or similar training via the project			
<b>► Laboratories with trained staff and consumables for collecting COVID-19 samples and transporting to National Public Health laboratory (Number, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	17.00	17.00	12.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
<b>► Targeted healthcare facilities with clinical capacity for COVID-19 patients (Percentage, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	56.00	56.00	62.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Numerator: Total number of targeted healthcare facilities with capacity to treat COVID-19 patients Denominator: Total number of targeted health care facilities for COVID-19 patients			
<b>► Doses of eligible COVID-19 vaccines delivered in-country (Number, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	2,000,000.00
Date	11-Jun-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
<b>► People trained on the installation, monitoring and maintenance of the cold chain equipment (Number, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	200.00
Date	12-Mar-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
<b>□ Women trained on the installation, monitoring and maintenance of the cold chain equipment-Female (Number, Custom Breakdown)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	100.00
Date	11-Jun-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
<b>► Expansion of functioning cold chain equipment and stored vaccines (Number, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	150.00



Date	12-Mar-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
<input type="checkbox"/> Expansion of functioning cold chain equipment and stored vaccines in urban, nomadic and desert areas- nomadic and desert areas (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	60.00
Date	04-Jun-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
▶ Oxygen plant installed and functional (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	3.00
Date	29-Mar-2022	29-Mar-2022	29-Mar-2022	31-Dec-2024
▶ Vaccination centers with a female vaccinator present (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	100.00
Date	15-Mar-2022	15-Mar-2022	15-Mar-2022	15-Mar-2022

Component 2: Communication campaign, community engagement and Behavior change				
▶ Country has developed a communication and risk communication plan including community engagement strategies (Yes/No, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Existence of a communication and risk communication plan			
▶ Radio Stations broadcast COVID-19 risk communication message (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	12.00	12.00	90.00
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	Cumulative number of COVID-19 sensitization campaigns conducted as per contextualized their risk communication and community engagement strategies			
▶ Gender sensitive educational materials on COVID-19 vaccines distributed (Yes/No, Custom)				



	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	07-May-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024
<b>► Grievances received and addressed within the defined timeframe (Percentage, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	2.00	2.00	90.00
Date	11-Jun-2021	14-Feb-2022	14-Feb-2022	31-Dec-2024

### Component 3: Implementation Management and Monitoring and Evaluation

#### ► M&E system established and implemented to monitor project progress (Yes/No, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	24-Mar-2020	14-Feb-2022	14-Feb-2022	31-Dec-2024
Comments:	M&E system has been established and implemented to monitor project progress			

#### ► Number of healthcare professionals and district investigation officers trained on detection and reporting, or investigation of AEFIs (Number, Custom)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	200.00
Date	29-Mar-2022	29-Mar-2022	29-Mar-2022	31-Dec-2024

#### Healthcare professionals and district investigation officers trained on detection and reporting, or investigation of AEFIs- Female (Number, Custom Breakdown)

	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	0.00	100.00
Date	17-May-2022	17-May-2022	17-May-2022	31-Dec-2024

## Performance-Based Conditions

### Data on Financial Performance

#### Disbursements (by loan)




Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed		% Disbursed
P173846	IDA-66200	Effective	USD	6.98	6.98	0.00	2.87	4.13		41%
P173846	IDA-69570	Effective	USD	14.00	14.00	0.00	0.55	11.55		4.5%
P173846	IDA-71880	Not Effective	USD	13.35	13.35	0.00	0.00	13.43		0%
P173846	IDA-D6180	Effective	USD	6.98	6.98	0.00	7.42	0.00		100%
P173846	IDA-D8700	Effective	USD	14.00	14.00	0.00	0.80	12.16		6.2%
P173846	IDA-E1040	Not Effective	USD	13.35	13.35	0.00	0.00	13.36		0%
P173846	TF-B5944	Effective	USD	1.20	1.20	0.00	0.00	1.20		0%

**Key Dates (by loan)**

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173846	IDA-66200	Effective	13-Apr-2020	08-May-2020	08-Jul-2020	30-Apr-2022	31-Dec-2024
P173846	IDA-69570	Effective	25-Jun-2021	27-Aug-2021	17-Dec-2021	31-Dec-2024	31-Dec-2024
P173846	IDA-71880	Not Effective	20-Jun-2022	--	--	31-Dec-2024	31-Dec-2024
P173846	IDA-D6180	Effective	13-Apr-2020	08-May-2020	08-Jul-2020	30-Apr-2022	31-Dec-2024
P173846	IDA-D8700	Effective	25-Jun-2021	27-Aug-2021	17-Dec-2021	31-Dec-2024	31-Dec-2024
P173846	IDA-E1040	Not Effective	20-Jun-2022	--	--	31-Dec-2024	31-Dec-2024
P173846	TF-B5944	Effective	25-Jun-2021	25-Aug-2021	17-Dec-2021	30-Apr-2022	30-Apr-2023

**Cumulative Disbursements**





### Restructuring History

Level 2 Approved on 27-Apr-2022

### Related Project(s)

P176345-Niger COVID-19 Emergency Response Project - Additional Financing ,P178894-Niger COVID-19 Emergency Response Project- Second Additional Financing